title: Liver disease associated with ZZ alpha1-antitrypsin deficiency and ursodeoxycholic acid therapy in children.
abstract: OBJECTIVE
  To investigate the effect of ursodeoxycholic acid (UDCA) in children with liver disease associated with ZZ alpha1-antitrypsin (AAT) deficiency.
  
  
  METHODS
  A total of 42 affected children received UDCA (30 mg x kg x day(-1)) and underwent clinical and biochemical follow-up at least yearly.
  
  
  RESULTS
  In group 1, 22 children whose mean initial gamma-glutamyl-transpeptidase (GGT) was 7.4 x N normalized serum liver test results after a mean treatment of 2.6 years. In 16 of these children, UDCA was discontinued. Relapse was observed in 11 children, and liver test results returned to normal after UDCA resumption. In the other 5 children, liver test results remained normal during a mean period of 2.5 years. In group 2, 11 children (mean initial GGT 12.8 x N) had improved liver test results after a mean treatment of 2.3 years. In group 3, 9 children (mean initial GGT 33.8 x N) had no liver test result improvement and evolution toward cirrhosis, requiring liver transplantation in 7. Most of the children in group 1 had normal results of clinical examination after UDCA treatment, versus none in group 3 (P < or = 0.00001). Initial GGT (P < or = 0.002) and total bilirubin (P < or = 0.05) levels were significantly lower in group 1 than in group 3. Combined initial values of GGT < or =5.5 x N and total bilirubin < or =66 micromol/L were associated with normalization of liver test results in 90% of children.
  
  
  CONCLUSIONS
  UDCA may significantly improve clinical status and liver test results in some children with liver disease associated with ZZ AAT deficiency. No beneficial effect of UDCA was shown in children with the most severe liver involvement. Initial levels of GGT and total bilirubin may be of prognostic value for therapy effectiveness.
authors.affiliation: Pediatric Hepatology and National Reference Centre for Biliary Atresia, France.
authors.forename: Panayotis
authors.initials: P
authors.lastname: Lykavieris
authors.forename: Béatrice
authors.initials: B
authors.lastname: Ducot
authors.forename: Alain
authors.initials: A
authors.lastname: Lachaux
authors.forename: Alain
authors.initials: A
authors.lastname: Dabadie
authors.forename: Pierre
authors.initials: P
authors.lastname: Broué
authors.forename: Jacques
authors.initials: J
authors.lastname: Sarles
authors.forename: Olivier
authors.initials: O
authors.lastname: Bernard
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Jacquemin
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008107:Liver Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D008111:Liver Function Tests; D008297:Male; D010641:Phenotype; D012008:Recurrence; D012189:Retrospective Studies; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*; D019896:alpha 1-Antitrypsin Deficiency / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D005723:gamma-Glutamyltransferase / Q000097:blood
chemical_list: D014580:Ursodeoxycholic Acid; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin